Surgical Treatment of Sacroiliac Joint Pain
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 07.01.91 alerts
Get alerted when Policy 07.01.91 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and medical necessity criteria for minimally invasive and open sacroiliac joint fusion/fixation procedures and devices for members of Blue Cross Blue Shield - Iowa (Wellmark), including device-specific guidance.
Coverage and Medical Necessity Criteria
Minimally Invasive SIJ Fusion - Medical Necessity
Minimally invasive transiliac triangular implant (iFuse) fixation/fusion is considered medically necessary when ALL of the following are met:
All listed criteria must be documented
Open SIJ Fusion - Medical Necessity
Open sacroiliac joint fusion is considered medically necessary for the following indications:
Open SIJF for other indications is investigational unless criteria above are met.
Medical necessity criteria for SIJ fusion/fixation
Covered when ALL of the following are met
Documentation of durations and therapies required
Use diagnostic SIJ block as confirmatory test when indicated
Technique is technically demanding
Candidate selection (mirror of RCT inclusion criteria)
Covered when ALL of the following are met
These mirror inclusion criteria used in key RCTs (INSITE, iMIA).
Diagnostic criteria (trial-based)
Covered when ALL of the following diagnostic criteria are met (as used in key trials):
Trial-based diagnostic algorithm
Expected clinical benefit and durability
Coverage considerations informed by outcomes:
Use these outcomes to inform expected benefit and durability
Non-triangular implant evidence summary
Evidence synthesis and implications for non-triangular SIJ implants:
Confidence in effect is limited
Comparative uncertainty remains
Controlled comparative trials are needed
Open SIJ fusion: clinical context and evidence selection
Open SIJ fusion context and evidence selection:
Evidence mainly from small retrospective case series
Outcomes evidence is limited
Overall evidence quality low for many open SIJF indications
Eligibility for minimally invasive SIJ fusion
Minimally invasive SIJ fusion may be considered medically necessary when ALL of the following are met:
Sourced from society guidance (ASPN, ISASS, NASS, NICE)
Indications for open SIJ fusion
Open SIJ fusion / fusion as adjunct may be considered in specific clinical contexts when indicated by the underlying condition:
Evidence primarily from small case series; open SIJF investigational for routine degenerative SIJ pain.
Covered when ALL of the following are met
Coverage supported when clinical and diagnostic criteria consistent with cited guidance and evidence are met
Aligns with NICE 2017/2022 and society statements
Candidate selection for SIJ fusion
Covered when ALL of the following are met (as supported by respondent input and diagnostic algorithm):
History should exclude conditions unlikely to respond to stabilization (eg inflammatory arthropathy, metastatic disease).
Use imaging to exclude alternative diagnoses; imaging is rarely diagnostic except in inflammatory disease.
Covered when ALL of the following are met
MIS SIJ fusion may be considered medically necessary when ALL criteria below are satisfied.
NASS/ISASS/ASPN guidance referenced; NASS recommends two injections with ≥75% reduction while ISASS/ASPN accept ≥50%
Covered with evidence and selection criteria
Evidence and expert organizations' commentary summarized:
References include Whang, Polly, Sturesson, Duhon, LOIS
Radiographic fusion rates reported in long-term follow-up
Aligns with society guidance and evidence limitations
Minimally invasive sacroiliac joint (SIJ) fixation/fusion procedures and implantation approaches that do not meet the specific clinical and diagnostic criteria outlined in this policy are considered investigational. This includes devices or techniques not listed in the policy and procedures described as “fusion” when they produce little or no radiographic bridging bone and therefore functionally represent fixation rather than arthrodesis.
The policy distinguishes between fixation and fusion: procedures labeled as fusion but that show minimal or absent bridging bone on radiographs may be more accurately characterized as fixation. Such distinctions affect how outcomes (radiographic fusion versus mechanical stabilization) are interpreted for coverage decisions.
A recent double‑blind, sham‑controlled randomized trial (Randers et al., 2024) of minimally invasive triangular‑implant SIJ fusion found no statistically significant difference in the primary pain outcome at 6 months between implant and sham groups. The trial’s short follow‑up was noted as a limitation; this blinded result differs from prior nonblinded RCTs and informs cautious interpretation of the overall evidence base when considering coverage.
Interventions using alternative implant designs or approaches (for example, various cannulated screws placed via iliosacral or posterolateral routes, and posterior distraction/allograft approaches) are discussed separately in the evidence review. These approaches differ in technique and in the available clinical data, and many rely on prospective cohort or case‑series evidence rather than randomized comparative studies.
Controlled evidence is insufficient to conclude superiority of non‑triangular implant designs over the transiliac triangular implant. Systematic reviews and pooled analyses have suggested worse or more heterogeneous outcomes for screw‑type and some other designs compared with the triangular transiliac implant, but direct comparative randomized data are limited.
Open SIJ fusion and other surgical approaches are inappropriate in contexts such as active infection, tumor unrelated to implant placement, acute traumatic instability, or when non‑surgical management is clearly the preferred treatment. Open procedures are reserved for the specific indications listed (eg, adjunct to sacrectomy, refractory infection, severe pelvic ring disruption, or as part of multisegment spinal constructs).
Procedures performed without a confirmed diagnosis of SIJ dysfunction, without documented response to a diagnostic image‑guided SIJ injection, or when pain is adequately controlled with non‑surgical care do not meet the diagnostic recommendations cited by guidance such as NICE and therefore may not be supported for coverage.
Conditions that are unlikely to benefit from SIJ stabilization or fusion include active inflammatory arthropathies and metastatic disease affecting the sacroiliac region. Such underlying conditions should be excluded by history, exam, and imaging before considering fusion.
Minimally invasive SIJ fusion is not indicated for patients with less than 6 months of SIJ pain or functional impairment, and should not be performed without an adequate trial of conservative therapy as specified in the policy.
The evidence quality across studies varies and commenters have noted inconsistency in diagnostic criteria and study designs. This variability and the lack of explicit, consistent exclusions in some studies underscore the need for careful patient selection based on the policy’s diagnostic and conservative‑therapy requirements.
Case reports and some series have described poor outcomes after bilateral SIJ fusion for degenerative SIJ syndrome; such reports are cited as cautionary examples and reinforce the need for cautious case selection and discussion of potential risks.
Reiterating the policy stance: minimally invasive SIJ fixation/fusion approaches or devices that do not meet the stated clinical, diagnostic, and device‑specific criteria are considered investigational and are not supported by this policy.
Many marketed SIJ implant systems lack published peer‑reviewed evidence; a 2021 review found no published evidence for many identified devices. Devices without supporting clinical evidence should be considered investigational until adequate data are available.
Performing SIJ fusion without diagnostic confirmation—history, ≥3 positive provocative maneuvers, and a confirmatory image‑guided diagnostic SIJ block—or in patient populations not represented in trials raises concerns about appropriateness and increases the likelihood that the procedure will be considered investigational or unsupported.
The results of the Randers sham‑controlled RCT, which showed no significant difference between fusion and sham at 6 months, affect coverage considerations by emphasizing the importance of rigorous diagnostic confirmation and conservative‑therapy failure before proceeding to fusion in routine practice.
Use of devices or approaches without adequate comparative evidence relative to established alternatives (notably the transiliac triangular implant studied in multiple trials) is discouraged; comparative uncertainty may lead to investigational determinations.
Open or minimally invasive SIJ fusion performed for unspecified SIJ dysfunction that does not meet the policy’s diagnostic and conservative‑therapy criteria may be considered investigational given the limited and low‑quality evidence for many indications.
Use of unlisted procedure codes (CPT 27299) or implantable devices without clinical documentation supporting medical necessity and appropriate device selection requires justification; absent supporting evidence and documentation, such coding or device use may not be supported.
The policy requires diagnostic confirmation: absence of a confirmatory fluoroscopy‑ or CT‑guided intra‑articular SIJ block demonstrating the required acute pain reduction, or fewer than 3 positive provocative maneuvers, may lead to noncoverage of SIJ fusion procedures.
Cases that lack required diagnostic confirmation (provocative testing and diagnostic intra‑articular block), have not completed adequate conservative therapy, or have alternative explanations for symptoms generally do not meet the policy criteria and may be considered non‑covered.
Although the document does not uniformly state explicit “not medically necessary” listings for every scenario, reviewers emphasize careful patient selection and adherence to the diagnostic algorithm to avoid inappropriate procedures.
The section highlights evidence gaps and includes yes/no assessments of items reviewed; it does not itself provide exhaustive not‑medically‑necessary lists but reinforces that evidence limitations and lack of diagnostic rigor should guide coverage decisions.
Procedure, Device and Regulatory Codes
| OUR | FDA product code cited for SIJ fixation/fusion devices |
| K110838 | iFuse® clearance |
| K162733 | iFuse® 3D clearance |
| K222605 | iFuse TORQ® clearance |
| K241574 | iFuse TORQ® clearance (additional) |
| K241504 | iFuse TORQ TNT™ clearance |
| K233508 | iFuse Bedrock Granite® clearance |
| K200696 | FIREBIRD SI Fusion System™ clearance |
| K121148 | SambaScrew® clearance |
| K140079 | Silex Sacroiliac Joint Fusion® clearance |
| K112028 | SI-LOK® Sacroiliac Joint Fixation System clearance |
| K190580 | NADIA™ SI Fusion System (DIANA) clearance |
| K231944 | CATAMARAN SI Joint Fusion System clearance |
| K230857 | TiLink-P SI Joint Fusion System clearance |
| K240720 | TiLink-P additional clearance |
| K242141 | TiLink-P additional clearance |
| K243835 | TiLink-P additional clearance |
| K232275 | Invictus® Spinal Fixation System clearance |
| K231744 | VyLink™ Spinal Screw System clearance |
| K232259 | Patriot-SI Posterior Implant System clearance |
| K250001 | Patriot-SI additional clearance |
| 27278 | Arthrodesis, sacroiliac joint, percutaneous, or minimally invasive, with image guidance, includes obtaining bone graft when performed, unilateral placement of intra-articular device(s), without cortical piercing. |
| 27279 | Arthrodesis, sacroiliac joint, percutaneous, or minimally invasive, with image guidance, includes obtaining bone graft when performed, unilateral placement of transarticular device(s) and/or intra-articular device(s) piercing the lateral or medial cortices of the ilium and the lateral cortex of the sacrum. |
| 27280 | Arthrodesis, sacroiliac joint, open, includes obtaining bone graft, including instrumentation, when performed. |
| 27299 | Unlisted procedure, pelvis, or hip joint. |
| C1737 | Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable). |
| Category I CPT® code for MIS SIJ fusion | MIS SIJ fusion has an assigned Category I CPT code effective January 1, 2015 (document references adoption but does not list exact numeric CPT code). |
Prior Authorization, Documentation, and Steps for Providers
Prior Authorization Required (when applicable)
Prior authorization not applicable for some indications; however, prior authorization is expected for minimally invasive SIJ fusion procedures when coverage criteria are being evaluated. Providers are responsible for obtaining any required prior authorization per payer rules and submitting complete clinical documentation to support medical necessity.
- Prior authorization applicability: procedures meeting medically necessary criteria may still require PA per payer administrative rules.
- Provider responsibilities: ensure PA submitted with required clinical documentation (see documentation callouts).
Prior Authorization and Clinical Prerequisites
Prior authorization submissions should include clear clinical prerequisites and a summary of required elements to support medical necessity.
- Summary of PA contents: symptom duration, baseline pain/disability scores (e.g., VAS/NRS, ODI), prior conservative therapies with dates and responses, physical exam findings including provocative test results, and imaging reports (lumbar, pelvic, SIJ).
- Required clinical prerequisites: ≥6 months of intensive nonoperative treatment (medication optimization, activity modification, bracing, targeted active therapeutic exercise), at least 6 weeks of PT unless documented intolerance, and at least one therapeutic SIJ injection trial.
Prior Authorization: Diagnostic Confirmation
Diagnostic confirmation must be documented in the PA. This includes history and physical exam consistent with SIJ pain, results of provocative maneuvers, imaging to exclude alternative pathology, and image-guided diagnostic SIJ block(s).
- Document history: pain localized caudal to L5, posterior SIJ region (Fortin's point) and impact on ADLs.
- Provocative testing: ≥3 positive provocative tests out of validated maneuvers (e.g., thigh thrust, compression, Gaenslen, distraction, Patrick/FABER).
- Imaging: plain radiographs and CT or MRI to exclude tumor, infection, inflammatory arthropathy, and to evaluate SIJ degeneration/injury.
- Diagnostic injection: fluoroscopy- or CT-guided intra-articular SIJ block(s) with documented percent pain relief and duration.
Prior Authorization: Diagnostic Criteria
PA should explicitly confirm that diagnostic criteria are met prior to approval decisions. Key diagnostic thresholds used in trials and guideline statements should be included in the submission.
- Diagnostic thresholds: at least 50% acute pain reduction after an image-guided intra-articular SIJ injection for the expected duration of anesthetic (some guidance and trials require ≥50% and some require ≥75% on two occasions).
- Provocative tests: documentation that ≥3 of 5 validated provocative tests reproduced typical pain.
- Symptom localization: pain caudal to L5, localized over posterior SIJ, and Fortin's point tenderness.
Investigation / Not Meeting Criteria
If the procedure does not meet the documented medical necessity criteria or required documentation is missing, the service is investigational and may be denied. Providers should ensure submissions demonstrate all required criteria.
- Investigational: minimally invasive fixation/fusion not meeting criteria is considered investigational and may be denied.
- Administrative action: lack of required clinical evidence or missing PA may trigger denial or referral for peer review.
Conservative Therapy Documentation Required
Comprehensive conservative therapy documentation is required in the PA and medical record. Lack of adequate conservative therapy documentation is a common basis for denial.
- Minimum conservative therapy: documentation of a minimum 6-month trial of intensive nonoperative treatment including medication optimization, activity modification, bracing, and targeted active therapeutic exercise.
- Physical therapy: at least 6 weeks of PT with active exercise or documentation of intolerance to PT.
- Therapeutic injection: at least one therapeutic SIJ corticosteroid injection trial documented.
Diagnostic Confirmation Required
Diagnostic confirmation must include documented response to an image-guided, contrast-enhanced intra-articular SIJ injection. Absence of documented diagnostic block results may lead to denial.
- Injection response: document percent pain reduction and duration for the expected anesthetic effect; trials and some guidance note ≥50% relief (some protocols require ≥75% on two occasions).
- Technique: image guidance (fluoroscopy or CT) and use of contrast should be documented.
- Number of confirmations: some protocols require confirmation on two separate occasions for higher thresholds (e.g., 75%).
Evidence Limitations May Trigger Coverage Scrutiny
Evidence limitations identified in the literature (e.g., short follow-up, industry sponsorship, lack of head-to-head comparative trials, and substantial crossover in RCTs) may trigger additional scrutiny of coverage decisions and requests for supporting documentation.
- Common limitations: many studies are industry-sponsored, nonrandomized cohorts, single-arm designs, or have incomplete follow-up and/or substantial crossover.
- Operational impact: when evidence is limited, payers may request more complete documentation of selection criteria, prior therapies, and functional outcomes to justify coverage.
Potential Triggers for Non‑Coverage
Potential triggers for non-coverage include missing documentation of required conservative treatment, lack of diagnostic confirmation with image-guided block, insufficient symptom duration, or absence of required physical exam findings.
- Missing conservative treatment: no documentation of ≥6 months of intensive nonoperative care.
- Missing diagnostic block: absence of image-guided intra-articular SIJ block results showing required percent pain relief.
- Insufficient exam/imaging: lack of ≥3 positive provocative tests or imaging to exclude alternative diagnoses.
Triggers for Denial
Submissions lacking the required elements below are at risk for denial. Providers should address each item explicitly in the PA and medical record.
- Minimum 6 months of symptoms and conservative care documented with dates and responses.
- Baseline and follow-up pain/disability scores (e.g., VAS/NRS, ODI) with numeric values.
- Physical exam: pain location, Fortin's point tenderness, and documentation of ≥3 positive provocative maneuvers.
- Imaging reports: lumbar spine, pelvis, and SIJ imaging excluding alternative pathology.
- Diagnostic injection details: image guidance modality, anesthetic used, percent pain relief, and duration; therapeutic injection record.
No Explicit Administrative Denial Triggers Stated — Provider Action
Some source materials and commentaries focus on evidence synthesis without listing explicit administrative denial triggers. When PA or documentation rules are not explicitly stated, providers should default to including complete diagnostic, conservative therapy, and outcome information as outlined above.
- If no explicit administrative denial triggers are listed, include full documentation of conservative therapy, diagnostic confirmation, imaging, exam findings, and functional scores.
- When guidance is silent on step therapy, follow payer-specific PA and medical necessity submission requirements.
Required Clinical Documentation
Required clinical documentation to include in the PA or medical record: history, exam findings, conservative care timeline and responses, baseline functional measures, imaging, and diagnostic/therapeutic injection documentation.
- History: symptom duration, localization (caudal to L5, posterior SIJ), prior lumbar fusion status if applicable.
- Exam: Fortin's point tenderness, ≥3 positive provocative tests with test names and dates.
- Conservative care: specific therapies, start/end dates, response to each modality, documentation of compliance.
- Pain/disability scores: baseline VAS/NRS and ODI (e.g., VAS/NRS ≥5 and ODI ≥30 often cited in guidelines).
- Imaging: plain radiographs and CT or MRI reports excluding infection, tumor, or inflammatory arthropathy.
- Diagnostic injection(s): image-guided intra-articular SIJ block(s) with percent pain relief and duration; record of at least one therapeutic corticosteroid injection.
Required Documentation — Evidence Citations
Required documentation should also reference supporting evidence and guideline citations where applicable to strengthen the clinical rationale for SIJ fusion.
- Include applicable guideline statements (e.g., ASPN, ISASS, NASS, NICE) and key trial citations (e.g., INSITE trial and follow-up publications) when clinical criteria are met.
- Attach relevant published outcomes (VAS, ODI changes) and any site-specific prospective cohort data if available.
No Documentation Requirements Provided in Source — Provider Action
Some source excerpts provide bibliographic commentary without explicit documentation requirements. When encountering such content, providers must still supply the full set of clinical documentation required by payer policy.
- Bibliographic comments alone are insufficient for PA — supply diagnostic, conservative therapy, exam, imaging, and injection records.
- If guidelines referenced do not specify exact administrative steps, follow payer PA form and documentation checklist.
Conservative Therapy Requirements and Stepwise Care
Conservative therapy requirements and expectations are consistent across major guidance: a minimum of 6 months of intensive nonoperative management is expected, including medication optimization, activity modification, and targeted active therapeutic exercise; stepwise care should be documented.
- Expected conservative therapies: NSAIDs, medication optimization (including adjuncts like nerve stabilizers or muscle relaxants), and at least 6 weeks of physical therapy.
- Step therapy: document progression through conservative options (medications → PT → injections → other nonsurgical modalities such as RFA where used).
- Recommended steps: NSAIDs, 4–6 weeks PT, at least one therapeutic SIJ injection; document reasons if any step was contraindicated or not tolerated.
Conservative Therapy and Selection
Clinical selection requires assessment of conservative therapy response and holistic patient evaluation (including psychosocial factors). Providers should document selection rationale and any contraindications to specified therapies.
- Selection and assessment: document psychosocial assessment, opioid status and mitigation plans, and rationale for proceeding to surgery.
- If PT or injections were not possible, document reason (intolerance, contraindication) with supporting records.
- Record prior surgical history (e.g., prior lumbar fusion) and its relation to current SIJ symptoms.
No Step Therapy Requirements Described in Source — Provider Action
When source content does not describe explicit step therapy rules, providers should still follow a stepwise conservative approach and document all prior nonoperative measures before surgical consideration.
- If no step therapy requirements are described by a guideline excerpt, include a clear timeline showing attempts at medications, PT, and at least one injection.
- Document clinical rationale for any deviation from standard stepwise care.
Clinical Background and Evidence Context
The sacroiliac joint (SIJ) is recognized as a potential source of low back and buttock pain. Surgical stabilization or fusion—either open or minimally invasive/transiliac—aims to reduce pain and improve function by mechanically stabilizing the joint and, when arthrodesis occurs, achieving bony fusion across the joint.
The evidence base for SIJ fusion includes mixed trial results: randomized controlled trials and nonblinded RCTs reporting benefits out to 1–2 years and a blinded sham‑controlled trial reporting no significant difference at 6 months. These differing trial designs and results must be considered together when assessing the overall strength of evidence.
Findings from the Randers sham‑controlled RCT attenuate confidence in unblinded trial results and underscore that blinded placebo‑controlled data can materially affect interpretation of benefits; this impacts how evidence is weighed for coverage, particularly for patients lacking rigorous diagnostic confirmation.
Caution is advised regarding use of devices lacking comparative peer‑reviewed evidence. Many implant designs and approaches have limited or single‑arm observational data; absence of direct comparisons to more established designs (eg, triangular transiliac implants) limits conclusions about relative safety and effectiveness.
Definitions and Device/Procedure Terms
Policy Revision History
Policy effective date recorded for sacroiliac joint fusion coverage criteria.
Category I CPT code for minimally invasive SIJ fusion adopted (effective Jan 1, 2015) as noted in coding history.
NICE published guidance (2017) supporting minimally invasive SIJ fusion with diagnostic confirmation and prior non-surgical management.
Document last reviewed and updated with evidence synthesis including RCTs, cohort studies, and guidance summaries (last_review date recorded).
Most recent review completed; policy status set to CURRENT with last_review dated 2026-01-01 and next_review scheduled 2026-01-01.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.